The young breast cancer patient therapy – new opportunities, new challenges
Languages of publication
The paper describes the case of a 31-year-old female patient with breast cancer with the abdominal metastases. This disease in young people usually has a more aggressive biological subtype, which significantly worsens the prognosis. In this patient aggressive treatment was used. It was effective and did not cause severe or long-term complications.
- 1. Batist G, Remakrishnan G, Rao CS et al. Reduced cardiotoxity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin with cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-54.
- 2. Batist G, Harris L, Azarina N et al. Improved anti-tumor response rate with decreased cardiotoxity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who haved received prior adjuvant doxorubicin: results of a retrospective analysys. Anticancer Drugs 2006; 17: 587-95.
- 3. Meiyuan X, Feifei Y, Sufen Y, Peng S. Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized trials. PloS One 2015; 10(7): e0133569
Publication order reference